Also trades as: 0J2O.L (LSE) · $vol 0M
HALO NASDAQ
Halozyme Therapeutics, Inc.
1W: +3.3%
1M: +13.8%
3M: +54.3%
YTD: +82.8%
1Y: +94.3%
3Y: +265.5%
5Y: +231.5%
$128.50
+0.49 (+0.38%)
Weekly Expected Move ±4.8%
$114
$120
$126
$132
$138
Credit Risk of going bust: lower than 70% of companies Debt: 12.8% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.58B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.58B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-03-21
Earliest Filing
2025-10-03
Latest Filing
partner: 7
target: 4
acquirer: 2
Counterparties (Filed by HALO)
13 relationshipsCompanies named in HALO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Elektrofi, Inc. | — | target | Target of a merger agreement entered into by Halozyme Therapeutics, Inc. | 2025-10-03 | View |
| Erraid Merger Sub Inc. | — | target | Wholly-owned subsidiary of Halozyme Therapeutics, Inc. used as the merger vehicle. | 2025-10-03 | View |
| Bank of America, N.A. | BACRP | partner | Counterparty to capped call transactions | 2022-08-18 | View |
| Mizuho Markets Americas LLC | — | partner | Counterparty to capped call transactions | 2022-08-18 | View |
| Bank of Montreal | BERZ | partner | Counterparty to capped call transactions | 2022-08-18 | View |
| Royal Bank of Canada | — | partner | Counterparty to capped call transactions | 2022-08-18 | View |
| Wells Fargo Bank, National Association | — | partner | Counterparty to capped call transactions | 2022-08-18 | View |
| Antares Pharma, Inc. | — | target | Target company acquired via tender offer and merger by Atlas Merger Sub, Inc. | 2022-05-24 | View |
| Atlas Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Halozyme Therapeutics, Inc. that acquired Antares Pharma, Inc. | 2022-05-24 | View |
| Antares Pharma, Inc. | ATRS | target | Target company in a cash tender offer and merger agreement with Halozyme Therapeutics, Inc. | 2022-04-13 | View |
| Atlas Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Halozyme Therapeutics, Inc. acting as the Purchaser in the merger. | 2022-04-13 | View |
| Seismic Software, Inc. | — | partner | Counterparty to Lease Assignment Agreement for office space | 2022-03-21 | View |
| Kilroy Realty L.P. | KRC | partner | Landlord in the office lease being assumed | 2022-03-21 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-30 | Officer/Director Change | View | |
| 2026-09-22 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-09-18 | Other Events; Exhibits | View | |
| 2026-09-16 | Other Events; Exhibits | View | |
| 2026-08-18 | Officer/Director Change | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Officer/Director Change | View | |
| 2026-05-11 | Earnings Release; Exhibits | View | |
| 2026-05-07 | Shareholder Vote | View | |
| 2026-04-30 | Officer/Director Change; Exhibits | View | |
| 2026-04-24 | Bylaws Amendment; Exhibits | View | |
| 2026-03-12 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-02-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-08 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-24 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-11-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR